Steven J. Padula - Concepedia

Author

Steven J. Padula

Boehringer Ingelheim (Germany)

Also Known As

S J Padula, S. J. Padula, S. Padula, S.J. Padula, STEVEN J. PADULA, Steven J Padula, Steven J. Padula, Steven Padula

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)UConn Health University of Connecticut Yale University

About

Steven J. Padula is an author at Boehringer Ingelheim (Germany) specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	1.9K
2	Allergy	4	4	841
3	Education	1	1	40
4	Health Sciences	1	1	76
5	Natural Sciences	1	1	13

Steven J. Padula

Publications

Citations

H-Index

Page 1

	Year	Citations
An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. Nancy H. Ruddle, Cheryl M. Bergman, Katherine McGrath, The Journal of Experimental Medicine ImmunotoxicologyHumoral ResponseImmunologyImmunodominanceImmunologic Mechanism	1990	693
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis Kim Papp, Andrew Blauvelt, Michael Bukhalo, New England Journal of Medicine	2017	504
The Nuclear Receptor PPARγ and Immunoregulation: PPARγ Mediates Inhibition of Helper T Cell Responses Robert B. Clark, David Bishop‐Bailey, Tatiana Estrada-Hernandez, The Journal of Immunology	2000	458
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study Brian G. Feagan, William J. Sandborn, Geert D’Haens, The Lancet InflammationRheumatologyPlacebo-controlled Phase 2Autoimmune DiseaseImmunology	2017	435
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei, Annals of the Rheumatic Diseases	2018	359
Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial James G. Krueger, Laura K. Ferris, Alan Menter, Journal of Allergy and Clinical Immunology ImmunologyClinical TrialsBiomarker ResultsClinical DermatologyPlacebo-controlled Trial	2015	246
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study Brian G. Feagan, Julián Panés, Marc Ferrante, The Lancet. Gastroenterology & hepatology Autoimmune DiseaseOpen-label Extension StudyImmunologyGastroenterologyClinical Gastroenterology	2018	156
Serologic Diagnosis of Lyme Borreliosis by Using Enzyme-Linked Immunosorbent Assays with Recombinant Antigens Louis A. Magnarelli, Jacob W. IJdo, Steven J. Padula, Journal of Clinical Microbiology	2000	88
Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study Ulrich Mrowietz, A. David Burden, Andreas Pinter, Dermatology and Therapy	2021	85
Molecular characterization and expression of p23 (OspC) from a North American strain of Borrelia burgdorferi Steven J. Padula, Alicia Sampieri, F. Dias, Infection and Immunity Ospc GeneMolecular CharacterizationImmunodeficienciesPathogenesisImmunology	1993	78

Page 1